Zervimesine, a Small Sigma‑2 Receptor Selective Modulator for Alzheimer's Disease

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Soluble amyloid-beta (Aβ) oligomers are implicated in synaptic and neuronal damage.
• Developing therapeutics that protect against Aβ toxicity is crucial for neurodegenerative diseases.

Purpose of the Study:

• To investigate the neuroprotective potential of Zervimesine.
• To characterize Zervimesine's pharmacological profile as an S2R modulator.

Main Methods:

• Zervimesine synthesis via organic chemistry.
• Assessment of blood-brain barrier penetration.
• Evaluation of S2R modulation selectivity and potency.
• Testing Zervimesine's efficacy against soluble Aβ oligomers in neuronal models.

Main Results:

• Zervimesine is a small molecule readily synthesized with minimal off-target effects.
• It exhibits potent and selective S2R modulation.
• Zervimesine demonstrates the ability to protect synapses and neurons from toxic Aβ oligomers.

Conclusions:

• Zervimesine is a promising neuroprotective agent.
• Its S2R modulator activity may underlie its ability to prevent Aβ-induced neurotoxicity.